Compare OPRX & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRX | ARMP |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 199.7M |
| IPO Year | 2008 | 1996 |
| Metric | OPRX | ARMP |
|---|---|---|
| Price | $8.37 | $3.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $12.60 | ★ $17.50 |
| AVG Volume (30 Days) | 128.5K | ★ 257.6K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.55 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,429,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $4.54 | $3.08 |
| 52 Week High | $22.25 | $14.98 |
| Indicator | OPRX | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 64.98 | 35.95 |
| Support Level | $7.04 | N/A |
| Resistance Level | $9.08 | $5.63 |
| Average True Range (ATR) | 0.38 | 0.49 |
| MACD | 0.08 | -0.08 |
| Stochastic Oscillator | 95.89 | 5.26 |
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.